Rmpl Pharma LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Rmpl Pharma LLP Pharmaceutical Export Portfolio Dataset — 13 Products, $438.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Rmpl Pharma LLP — Pharmaceutical Exporter Profile (2026) | 13 Products, $438.6K Trade | TransData Nexus

Rmpl Pharma LLP

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $438.6K Total Trade · DGFT Verified

Rmpl Pharma LLP is an Indian pharmaceutical exporter with a total trade value of $438.6K across 13 products in 3 therapeutic categories. Based on 326 verified export shipments from Indian Customs (DGFT) records, Rmpl Pharma LLP is the #1 Indian exporter in 2 products including Cladribine, Levodopa Carbidopa. Top exports include Lenalidomide ($145.7K), Rituximab ($92.7K), Daratumumab ($55.0K).

Rmpl Pharma LLP — Export Portfolio & Destination Treemap

Rmpl Pharma LLP pharmaceutical export portfolio — 13 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Rmpl Pharma LLP? — Company Overview & Market Position

RMPL Pharma LLP, established on May 16, 2015, is a Mumbai-based pharmaceutical exporter specializing in oncology and specialized products. As a part of the Royal Group of companies, which dates back to 1944, RMPL Pharma has built a reputation as a leading merchant exporter in India. The company is registered under the Corporate Identification Number (CIN) AAD-9570. While specific revenue figures are not publicly disclosed, RMPL Pharma operates with a total obligation of contribution of ₹98,000. The firm employs a dedicated team of 23 professionals, including designated partners Mahendra Mukundlal Gandhi and Asan Mohideen Nagoormeeran Sheik Packeer. Their official website is www.rmplpharma.com.

What Does Rmpl Pharma LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Lenalidomide$145.7K 2Rituximab$92.7K

Product Portfolio — Top 13 by Export Value

Rmpl Pharma LLP exports 13 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Lenalidomide	Advanced Oncology	$145.7K	82	0.0%	10
2	Rituximab	Advanced Oncology	$92.7K	55	0.5%	10
3	Daratumumab	Advanced Oncology	$55.0K	4	4.1%	8
4	Cladribine	Advanced Oncology	$37.3K	5	16.0%	1
5	Ibrutinib	Advanced Oncology	$29.2K	25	2.9%	6
6	Dacarbazine	Advanced Oncology	$27.9K	67	2.0%	14
7	Ifosfamide	Advanced Oncology	$18.6K	23	0.8%	14
8	Regorafenib	Advanced Oncology	$9.1K	3	0.9%	6
9	Axitinib	Advanced Oncology	$7.2K	9	7.7%	3
10	Cabozantinib	Advanced Oncology	$6.5K	19	5.1%	4
11	Procarbazine	Advanced Oncology	$5.6K	16	2.1%	7
12	Levodopa Carbidopa	Combination Drugs	$2.1K	4	27.8%	1
13	Saxagliptin	Advanced Diabetes Medications	$1.6K	14	0.0%	10

Rmpl Pharma LLP exports 13 pharmaceutical products across 3 therapeutic categories with a total export value of $438.6K. The company is the #1 Indian exporter in 2 products: Cladribine, Levodopa Carbidopa. The top category is Advanced Oncology (99.2% of portfolio), followed by Combination Drugs (0.5%), indicating a concentrated portfolio with the top 5 products accounting for 82.1% of total export value.

Rmpl Pharma LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

RMPL Pharma LLP operates from its headquarters located at Office No. S-1, Ground Floor, Sharda Chambers Premises Co-Operative Society Limited, New Marine Lines, Churchgate, Mumbai, Maharashtra, India. The company specializes in the export and wholesale distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details about manufacturing plant locations and capacities are not publicly disclosed, RMPL Pharma sources its products from reputed Indian and multinational manufacturers, ensuring adherence to international quality standards.

3Key Leadership

The leadership team at RMPL Pharma LLP comprises:

Mahendra Mukundlal Gandhi: Designated Partner since May 16, 2015.

Asan Mohideen Nagoormeeran Sheik Packeer: Designated Partner since May 16, 2015.

These leaders bring extensive experience to the company, driving its strategic direction and operational excellence.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Rmpl Pharma LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

RMPL Pharma LLP has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports a diverse range of pharmaceutical products, primarily focusing on oncology and specialized medications. While specific regulatory filings and approvals are not publicly disclosed, RMPL Pharma's adherence to international quality standards, as evidenced by certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, underscores its commitment to meeting the stringent requirements of these markets.

2Emerging Markets

RMPL Pharma LLP has expanded its reach to emerging markets across Africa, Latin America, and Southeast Asia. The company's export activities span over 25 countries, including Saudi Arabia, Yemen, Turkey, Syria, Lebanon, Kenya, Uganda, Hong Kong, Egypt, Libya, Sri Lanka, Tanzania, Djibouti, Ghana, Iran, Jordan, Thailand, Dubai, Somaliland, and Iraq. While specific details about WHO prequalification are not publicly available, RMPL Pharma's adherence to international quality standards, as evidenced by certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, suggests a commitment to meeting the requirements for access to these markets.

3Geographic Strategy

Rmpl Pharma LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding RMPL Pharma LLP's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the company's adherence to international quality standards, as evidenced by certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, indicates a commitment to meeting the stringent requirements of regulated markets, including the United States.

2WHO & EU GMP

RMPL Pharma LLP holds certifications that reflect its commitment to quality and compliance with international standards:

WHO-GMP Certification: Indicates adherence to the World Health Organization's Good Manufacturing Practices, ensuring the quality of pharmaceutical products and good distribution and trading practices.

ISO 9001:2015 Certification: Demonstrates the company's ability to meet international standards, bringing standardized practices to organizational and administrative work.

Rmpl Pharma LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the oncology and specialized pharmaceutical export sector, RMPL Pharma LLP faces competition from both Indian and multinational companies. While specific market share data is not publicly available, RMPL Pharma's focus on high-quality products, adherence to international standards, and broad geographic reach position it competitively in the market. The company's commitment to ethical business practices and financial discipline further enhances its standing among competitors.

2Key Differentiators

RMPL Pharma LLP distinguishes itself through several key factors:

Extensive Product Range: Offering over 6,000 marketed products, including original brands and true generics, primarily in oncology and specialized therapeutic areas.

International Certifications: Holding certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, demonstrating adherence to global quality standards.

Global Reach: Exporting to over 25 countries across Africa, the Middle East, Europe, and Southeast Asia, showcasing a diversified geographic strategy.

Buyer Due Diligence Brief — Evaluating Rmpl Pharma LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

RMPL Pharma LLP demonstrates a strong track record in the pharmaceutical export sector, with a total export value of $439,000 USD and 326 shipments across 13 products in three therapeutic categories. The company's portfolio concentration is notable, with the top five products accounting for 82.1% of exports. This concentration indicates a focused approach to product offerings. The company's adherence to international quality standards, as evidenced by certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

WHO-GMP Certification: Indicates adherence to the

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Rmpl Pharma LLP

How many pharmaceutical products does Rmpl Pharma LLP export from India?

Rmpl Pharma LLP exports 13 pharmaceutical products across 3 therapeutic categories. The top exports are Lenalidomide ($145.7K), Rituximab ($92.7K), Daratumumab ($55.0K), Cladribine ($37.3K), Ibrutinib ($29.2K). Total export value is $438.6K.

What is Rmpl Pharma LLP's total pharmaceutical export value?

Rmpl Pharma LLP's total pharmaceutical export value is $438.6K, based on 326 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Rmpl Pharma LLP the #1 Indian exporter?

Rmpl Pharma LLP is the #1 Indian exporter in 2 products: Cladribine (16.0% market share), Levodopa Carbidopa (27.8% market share).

What therapeutic categories does Rmpl Pharma LLP cover?

Rmpl Pharma LLP exports across 3 therapeutic categories. The largest are Advanced Oncology (99.2%, 11 products), Combination Drugs (0.5%, 1 products), Advanced Diabetes Medications (0.4%, 1 products).

Get Full Rmpl Pharma LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.